Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of pembrolizumab in combination with paclitaxel for hormone receptor-positive metastatic breast cancer with high tumor mutational burden
KCT0007042Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of pembrolizumab and paclitaxel in breast cancer, sponsored by Merck & Co. Started Mar 2022; status: completed.
02
Drugs
pembrolizumabpaclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on KCT0007042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0007042.